Oliveira, M., Sonnenblick, A., Rugo, H. S., Jung, K. H., Yam, E. G., Hurvitz, S. A., . . . Sohn, J. (2023 Supplement 16). Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC). Journal of Clinical Oncology, 41, 1061-1062.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Oliveira, Mafalda, et al. "Interim Analyses (IA) of the Giredestrant (G), G + Abemaciclib (A), and G + Ribociclib (R) Arms in MORPHEUS Breast Cancer (BC): A Phase I/II Study of G Treatment (tx) Combinations in Patients (pts) with Estrogen Receptor-positive, HER2-negative Locally Advanced/metastatic BC (ER+, HER2– LA/mBC)."
Journal of Clinical Oncology 41 (2023 Supplement 16): 1061-1062.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Oliveira, Mafalda, et al. "Interim Analyses (IA) of the Giredestrant (G), G + Abemaciclib (A), and G + Ribociclib (R) Arms in MORPHEUS Breast Cancer (BC): A Phase I/II Study of G Treatment (tx) Combinations in Patients (pts) with Estrogen Receptor-positive, HER2-negative Locally Advanced/metastatic BC (ER+, HER2– LA/mBC)."
Journal of Clinical Oncology, vol. 41, 2023 Supplement 16, pp. 1061-1062.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.